Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies
WW International (NASDAQ: WW ) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE: LLY ) LillyDirect digital health care platform, expanding access to branded GLP-1 weight-loss medications alongside clinical and behavioral support services. • Eli Lilly stock is surging to new heights today. What’s driving LLY stock higher? Weight Watchers Expands GLP-1 Access Through LillyDirect The addition to LillyDirect aligns with Weight Watchers' strategy to broaden access to GLP-1 treatments through its Med+ program, which provides patient support before, during and after treatment. LillyDirect connects patients with independent care options, pharmacy fulfillment resources, and educational content as demand for GLP-1 medications continues to increase . Weight Watchers said its Med+ offering complements these services with a comprehensive care model designed to support long-term weight management. Ascidian, Eli Lilly Partner On RNA-Based Kidney Disease Therapies Ascidian Therapeutics on Wednesday ... Full story available on Benzinga.com
Read Full Article at Benzinga →